Clindamycin 2-Phosphate
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-04542 |
| CAS | 24729-96-2 |
| Molecular Weight | 504.96 |
| Molecular Formula | C18H34ClN2O8PS |
| Purity | >98% |
Online Inquiry
Description
Clindamycin Phosphate is a lincosamide antibiotic for Plasmodium falciparum with IC50 of 12 nM. It is usually used to treat infections with anaerobic bacteria, but can also be used to treat protozoal diseases, such as malaria. It is a common drug used to treat topical acne and can be effective against some methicillin-resistant Staphylococcus aureus (MRSA) infections. An impurity of Clindamycin.
Specification
| Synonyms | Methyl 7-Chloro-6,7,8-trideoxy-6-trans-(1-methyl-4-propyl-L-2-pyrrolidine-carboxamido)-1-thio-L-threo-α-D-galactooctopyranoside 2-(Dihydrogen Phosphate); 7(S)-Chloro-7-deoxylincomycin 2-Phosphate; Cleocin T; Cleocin Phosphate; Clinadac; Clindagel; Clindesse; Clindets; Dalacin P; Dalacin T; NSC 618653 |
| Storage | Store at 2-8°C under inert atmosphere |
| IUPAC Name | [(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-[[(2S,4R)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate |
| Canonical SMILES | CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)OP(=O)(O)O)O)O)C(C)Cl |
| InChI | InChI=1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1 |
| InChI Key | UFUVLHLTWXBHGZ-MGZQPHGTSA-N |
| Source | Semi-synthetic |
Properties
| Appearance | White Solid |
| Antibiotic Activity Spectrum | Gram-positive bacteria |
| Boiling Point | 159°C |
| Melting Point | 187-192°C (dec.) |
| Density | 1.41±0.1 g/cm3 (Predicted) |
| Solubility | Soluble in DMSO (Slightly), Methanol (Slightly, Heated) |
Reference Reading
1.Clindamycin Phosphate Absorption from Nanoliposomal Formulations through Third-Degree Burn Eschar.
Ghaffari A1, Manafi A2, Moghimi HR3. World J Plast Surg. 2015 Jul;4(2):145-52.
BACKGROUND: It has been shown that topical nanoliposomal formulations improve burn healing process. On the other hand, it has been shown that liposomal formulations increase drug deposition in the normal skin while decrease their systemic absorption; there is not such data available for burn eschar. Present investigation studies permeation of clindamycin phosphate (CP) through burn eschar from liposomal formulations to answer this question. In this investigation, permeation of CP through fully hydrated third-degree burn eschar was evaluated using solution, normal nanoliposomes and ultradeformable nanoliposomes.
2.Randomized, Observer-blind, Split-face Compatibility Study with Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.75% gel and Facial Foundation Makeup.
Bhatia N1, Pillai R2. J Clin Aesthet Dermatol. 2015 Sep;8(9):25-32.
BACKGROUND: Cosmetic compatibility in the treatment of acne is an important issue significantly impacting quality of life, but often overlooked, as dermatologists commonly recommended avoidance of cosmetic foundations when treating adult female patients. Fixed combinations of clindamycin/benzoyl peroxide are widely used in the treatment of acne, but little is known about the impact of their concomitant use with facial foundation.
3.Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M1, Guarneri F1, Borgia F1, Pollicino A2, Altavilla G2, Cannavò SP1. J Dermatolog Treat. 2016 Mar;27(2):148-52. doi: 10.3109/09546634.2015.1086478. Epub 2015 Sep 24.
BACKGROUND: Epidermal growth factor receptor inhibitors are recent antineoplastic treatments used for the treatment of some non-cutaneous tumours, which aberrantly express EGFR. Because of their specificity, these drugs have low systemic toxicity, but frequent undesired cutaneous effects, the most common of which is an acneiform eruption, occurring after 1-3 weeks of treatment. Management of this rash is not well standardized.
Recommended Products
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
